| Features: | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Linalool — Linalool is a naturally occurring acyclic monoterpene tertiary alcohol and volatile terpene found in many essential oils, including lavender, coriander, basil, rosewood, and citrus-associated oils. It is formally classified as a small-molecule phytochemical / monoterpenoid fragrance and flavor compound, commonly abbreviated as LIN or Lin. It exists as enantiomers with different odor profiles and biological handling. In oncology research, linalool is best treated as a preclinical bioactive terpene with in-vitro and limited animal-model anticancer signals, not as a clinically validated anticancer therapy. Primary mechanisms (ranked):
Bioavailability / PK relevance: Linalool is volatile and lipophilic, with systemic exposure possible after oral, inhaled, and transdermal routes, but therapeutic plasma levels for anticancer effects remain uncertain. Human oral PK methods have been developed, and inhalation/transdermal studies support absorption, but most anticancer experiments use concentrations that are difficult to map directly to achievable human exposure. In-vitro vs systemic exposure relevance: Many anticancer studies use high micromolar to millimolar linalool concentrations, especially in lung, liver, leukemia, prostate, and colon cancer cell models. These levels may exceed realistic systemic exposure from food, fragrance, aromatherapy, or ordinary essential-oil use. Direct anticancer interpretation should therefore be concentration-constrained. Clinical evidence status: Preclinical. Linalool itself has no established cancer-treatment indication. Human studies involving linalool-rich essential oils or aromatherapy are mainly supportive-care studies for anxiety, sleep, pain, or procedural distress, not tumor-response trials. Regulatory status is primarily as a flavor/fragrance substance, not as an approved oncology drug. Linalool Cancer Mechanism Table
TSF legend: P: 0–30 min R: 30 min–3 hr G: >3 hr |
| Source: HalifaxProj(inhibit) |
| Type: |
| Interleukin-6 (IL-6) is a cytokine that plays a significant role in inflammation and the immune response. It is produced by various cell types, including T cells, B cells, macrophages, and fibroblasts. IL-6 can promote tumor cell proliferation and survival. Many cancer cells produce IL-6, which can create an autocrine loop that supports their growth. IL-6 is a high-value inflammatory biomarker in cancer, reporting cytokine burden, catabolic stress, and STAT3-linked survival signaling. While not tumor-specific, elevated and rising IL-6 strongly predicts poor prognosis and limited treatment tolerance, making it an important system-state indicator alongside CRP and ferritin. |
| 6482- | LIN, | Pharmacological and molecular insights into linalool-rich Coriandrum sativum essential oil: Anticonvulsant, analgesic, anti-inflammatory, and antioxidant potential in rodent models |
| - | Review, | Nor, | NA |
Query results interpretion may depend on "conditions" listed in the research papers. Such Conditions may include : -low or high Dose -format for product, such as nano of lipid formations -different cell line effects -synergies with other products -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:% IllCat:% CanType:% Cells:% prod#:410 Target#:158 State#:% Dir#:%
wNotes=0 sortOrder:rid,rpid